{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
nonoxynol-9
to a specific field?
Class (Stereo):
CHEMICAL (ACHIRAL)
Oxdralazine is a peripheral vasodilator that was studied for patients with severe essential hypertension. The clinical trial has shown that at the end of the third month 25 patients on the triple regimen (chlorthalidone plus oxdralazine plus propranolol) achieved a stable diastolic blood pressure of 90 mm Hg or less. However, information about the further development of this drug is not available.
Status:
Investigational
Source:
NCT03563599: Phase 2 Interventional Completed Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Q203 (6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidin-1-yl)benzyl)imidazo [1,2-a]pyridine-3-carboxamide) is an an imidazopyridine antitubercular
compound. Q203 targets the cytochrome b subunit (QcrB) of the cytochrome bc1 complex. This complex is an essential component of the respiratory electron transport chain of ATP synthesis. Q203 inhibited the growth of multidrug-resistant (MDR) and extensively drug-resistant (XDR) M. tuberculosis clinical isolates in culture broth medium in the low nanomolar range and was efficacious in a mouse model of tuberculosis at a dose less than 1 mg per kg body weight, which highlights the potency of this compound. In addition, Q203 displays pharmacokinetic and safety profiles compatible with once-daily dosing. Q203 is a promising new clinical candidate for the treatment of tuberculosis.
Status:
Investigational
Source:
INN:irsenontrine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04470089: Phase 2 Interventional Terminated Acute Pharyngitis
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (RACEMIC)
Sudexanox is a xanthone derivative patented by French pharmaceutical company Roussel-UCLAF for the treatment of allergy, allergic asthma, and asthmatic bronchitis. In preclinical studies, Sudexanox possesses potent activity in the IgE-induced rat passive cutaneous anaphylaxis model.
Status:
Investigational
Source:
NCT03086226: Phase 2 Interventional Completed Mycetoma
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ravuconazole is a triazole with antifungal properties that inhibits cytochrome P450 sterol 14a-demethylase, an enzyme involved in sterol synthesis, resulting in lysis of the fungal cell wall and fungal cell death. It was investigated for the treatment of aspergillosis, candidiasis, and onychomycosis, but these studies were discontinued. Ravuconazole is now in phase II clinical trials to investigate efficacy in preventing fungal infections in patients undergoing chemotherapy and stem cell transplantation.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Davasaicin is a synthetic derivative of capsaicin, developed at the Korea Research Institute of Chemical Technology. Davasaicin possesses very potent analgesic activity, demonstrated in several animal models, such as phenylbenzoquinone-induced writhing test, tail-flick test in mice and adjuvant arthritic flexion test in rats. When administered topically, davasaicin has an antipruritic effect in the mouse model.
Status:
Investigational
Source:
NCT00162799: Phase 2 Interventional Completed Insulin Resistance
(2002)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Class (Stereo):
CHEMICAL (UNKNOWN)
Conditions:
Furfenorex (unde brand name Frugalan), was used against obesity as an appetite suppressant. One of its metabolite was metamphetamine, which lead to the abuse to the drug. That is why this drug is no longer marketed
Status:
Investigational
Source:
Am J Physiol Gastrointest Liver Physiol. Jun 2006;290(6):G1089-95.: Not Applicable Veterinary clinical trial Completed N/A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Biologically, methanogens in the colon can use carbon dioxide and hydrogen to produce methane as a by-product. It was previously considered that humans do not utilize methane. However, in a recent study on rodents, results demonstrated that methane could exert anti-inflammatory, anti-oxidant and anti-apoptotic effects. Furthermore, it has bee suggested, that methane-rich saline could be a promising therapeutic agent for clinical treatment of pancreatitis. Methane gas may also be a promising option for the clinical treatment of Acute Lung Injury and Spinal Cord Injury. The exact mechanism underlying the antioxidative, anti-inflammatory, and antiapoptotic activities of methane is not obvious. Different researchers have proposed different hypotheses. Some have hypothesized that methane might accumulate transiently at the interfaces of cell membranes, thereby changing the physicochemical properties or the in-situ functionality of proteins embedded within this environment. Other investigators have suggested that methane could exert effects on membrane channels affecting G-proteins, membrane or receptor-mediated signaling, or acetylcholine-activated ion channel kinetics. It is unknown if mammalian cells contain an oxygenase that is capable of using methane as a substrate, or if the biological effects of methane are caused by the formation of small amounts of the reactive alcohol, methanol, and/or changes in the redox milieu of the cell due to changes in NAD(P)+/NAD(P)H ratio, and whether or not there is a cellular “receptor” for methane. There are also questions remaining around the difference between intraperitoneal vs inhaled administration of methane.
